Brief Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advancedat a late stage, far along tumors.
Intervention / Treatment
- Drug: MDX2004
Inclusion Criteria:
- Participant must be ≥ 18 years of age.
- Histologically or cytologically confirmed diagnosis of locally advanced or metastatic malignancy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- All participants should have at least 1 measurable site of disease according to RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
- Adequate hematologic, hepatic and renal function.
- All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consent.